Antibody Detecting Conformationally Altered p53 Epitope
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods fail to effectively detect conformationally altered isoforms of the p53 protein, which are associated with Alzheimer's disease and cognitive impairment, due to the masked nature of the linear epitope in the wild-type protein and the complexity of post-translational modifications.
Innovation Solution
Development of a monoclonal antibody specifically recognizing the exposed linear epitope (RRTEEENLRKKGEPHH) in the DNA binding domain of the p53 protein, which is altered in Alzheimer's disease, allowing for the detection of conformationally altered isoforms in biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used to detect p53 protein, then the wild-type p53 can be detected, but conformationally altered isoforms associated with Alzheimer's disease cannot be detected due to the masked linear epitope
Solution Approach 1:
The invention changes the conformational state parameter of the p53 protein by inducing unfolding or conformational alteration, which transforms the masked linear epitope into an exposed state that can be detected by antibodies. This parameter change resolves the contradiction by making the previously undetectable epitope accessible while maintaining the ability to detect wild-type p53.
Solution Approach 2:
The invention introduces chaperone proteins or denaturing agents as intermediaries that facilitate the exposure of the linear epitope on p53. These intermediaries mediate the conformational change required to expose the epitope without permanently altering the protein, enabling detection of conformationally altered isoforms while preserving wild-type detection capability.
2Measurement precision
If conformationally specific antibodies are used to detect altered p53 isoforms, then detection of mutated p53 is possible, but the masked linear epitope in wild-type p53 remains undetectable
Solution Approach 1:
The invention employs dynamic conformational changes in the p53 protein, allowing it to transition between folded and unfolded states. This dynamic behavior enables the linear epitope to be exposed temporarily for antibody binding, resolving the contradiction between maintaining wild-type conformation and exposing the masked epitope for detection.
Solution Approach 2:
By changing the conformational parameter of p53 through controlled unfolding or chaperone interaction, the invention makes the linear epitope accessible to antibodies without permanently disrupting the protein structure. This reversible parameter change allows both wild-type and altered isoform detection.
3Reliability
If the p53 protein maintains its wild-type conformation, then DNA binding activity is preserved, but the linear epitope remains masked and unavailable for antibody recognition
Solution Approach 1:
The invention uses chaperone proteins as intermediaries that bind to p53 and induce conformational changes exposing the linear epitope. These intermediaries facilitate epitope exposure without permanently compromising p53's biological activity, as the protein can return to its functional conformation after detection.
Solution Approach 2:
The invention exploits the dynamic nature of protein conformation, allowing p53 to reversibly transition between functional and detection-ready states. This dynamic approach preserves biological reliability while enabling epitope accessibility for diagnostic purposes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody enables accurate diagnosis and prognosis of Alzheimer's disease and predisposition to cognitive impairment, demonstrating a significant correlation with age and cognitive status, serving as a valuable diagnostic and prognostic tool.
Implementation Method 1
Development of a monoclonal antibody specifically recognizing the exposed linear epitope (RRTEEENLRKKGEPHH) in the DNA binding domain of the p53 protein
Data Source
AI summary
The invention relates to an anti-human p53 antibody suitable for specifically binding a linear epitope which is exposed only in a conformationally altered isoform of the characteristic p53 protein of patients with Alzheimer's disease or prone to develop Alzheimer's disease or cognitive impairment during ageing. Methods and diagnostic and prognostic kits are also described.